English
Home > Products > CAS NO 183321-74-6

China CAS NO 183321-74-6 Factory

Getting buyer gratification is our company's purpose endlessly. We will make good attempts to produce new and top-quality products, meet up with your specific requirements and provide you with pre-sale, on-sale and after-sale expert services for CAS NO 183321-74-6,183321-74-6,Erlotinib API,Erlotinib, We never stop improving our technique and high quality to maintain up with the enhancement trend of this industry and fulfill your pleasure effectively. For anyone who is fascinated within our solutions, you should get in touch with us freely.
CAS NO 183321-74-6, Our solutions are mainly exported to Europe, Africa, America, the Middle East and Southeast Asia and other countries and regions. We now have enjoyed a great reputation among our customers for quality products and good services.We would make friends with businessmen from at home and abroad, following the purpose of "Quality First, Reputation First, the Best Services."

Related Products

Hot Products

  • Upadacitinib

    Upadacitinib

    Product Name:Upadacitinib
    Molecular Formula:C17H19F3N6O
    Molecular Weight;380.37
    CAS Registry Number;1310726-60-3
  • Atropine

    Atropine

    Product Name:Atropine
    Molecular Formula:C17H23NO3
    Molecular Weight;289.37
    CAS Registry Number;51-55-8
  • 5-Chloromethyl-2H-1,2,4-triazolin-3-one

    5-Chloromethyl-2H-1,2,4-triazolin-3-one

    Product Name:5-Chloromethyl-2H-1,2,4-triazolin-3-one
    Molecular Formula:C3H4ClN3O
    Molecular Weight:133.54
    CAS Registry Number:252742-72-6
  • 4-Carboxyphenylboronic acid

    4-Carboxyphenylboronic acid

    Product Name:4-Carboxyphenylboronic acid
    Molecular Formula:C7H7BO4
    Molecular Weight:165.94
    CAS Registry Number:14047-29-1
  • 4-Nitrophenyl chloroformate

    4-Nitrophenyl chloroformate

    Product Name:4-Nitrophenyl chloroformate
    Molecular Formula:C7H4ClNO4
    Molecular Weight:201.56
    CAS Registry Number:7693-46-1
  • Stanozolol

    Stanozolol

    Product Name:Stanozolol
    Molecular Formula:C21H32N2O
    Molecular Weight:328.49
    CAS Registry Number;10418-03-8
  • Related Blog
  • Reviews

  • What Is Misoprostol Used For?

    Misoprostol, a derivative of prostaglandin E1, can be used in the treatment of duodenal ulcer, the prevention of anti-inflammatory induced peptic ulcer and the prevention of early pregnancy.It has the function of inhibiting the secretion of gastric acid and preventing the formation of ulcer, thus protecting the gastric mucosa...

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept